Keros Therapeutics, Inc.
KROS Nasdaq
SEC CIK 1664710
Follow Keros Therapeutics
Weekly email: filings, results
Revenue, last quarter
$40M
+180.5% vs same quarter last year
Net income
$14.2M
+294.4% vs same quarter last year
EPS, diluted
$0.70
+488.9% vs same quarter last year
Operating cash flow
$3.4M
+4.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $244.1M | $87M |
| FY24 | $3.6M | −$187.4M |
| FY23 | $151K | −$153M |
| FY22 | $0 | −$104.7M |
| FY21 | $20.1M | −$58.7M |
| FY20 | $0 | −$45.4M |
| FY19 | $10M | −$12.3M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | 27.7% | 35.7% |
| FY24 | −5939% | −5277.5% |
| FY23 | −112543.7% | −101319.2% |
| FY22 | - | - |
| FY21 | −280.5% | −292.3% |
| FY20 | - | - |
| FY19 | −105.6% | −123.4% |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $106M |
| FY24 | −$162.8M |
| FY23 | −$127M |
| FY22 | −$71.3M |
| FY21 | −$63.2M |
| FY20 | −$37.2M |
| FY19 | −$16.3M |
| FY18 | - |
- Keros Therapeutics
- Healthcare median
Show the numbers
| Year | Keros Therapeutics | Healthcare median |
|---|---|---|
| FY25 | 35.7% | −30.6% |
| FY24 | −5277.5% | −47% |
| FY23 | −101319.2% | −58% |
| FY22 | - | −80.4% |
| FY21 | −292.3% | −71.8% |
| FY20 | - | −62.2% |
| FY19 | −123.4% | −46.2% |
| FY18 | - | −49.6% |